Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia
Published:February 02, 2021DOI:https://doi.org/10.1016/S0140-6736(21)00234-8
